Belluscura Valuation
Is BELL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BELL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate BELL's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BELL's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BELL?
Key metric: As BELL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is BELL's PS Ratio? | |
|---|---|
| PS Ratio | 12x |
| Sales | US$1.80m |
| Market Cap | US$21.67m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 11.5x |
| Enterprise Value/EBITDA | -1.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BELL's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 14.8x | ||
EMVC EMV Capital | 6x | 49.2% | UK£10.8m |
AGL ANGLE | 16.3x | 51.5% | UK£33.1m |
POLX Polarean Imaging | 12.6x | 49.6% | UK£18.7m |
OBI Ondine Biomedical | 24.2x | 66.0% | UK£22.9m |
BELL Belluscura | 12x | 151.8% | UK£17.3m |
Price-To-Sales vs Peers: BELL is good value based on its Price-To-Sales Ratio (12x) compared to the peer average (14.8x).
Price to Sales Ratio vs Industry
How does BELL's PS Ratio compare vs other companies in the GB Medical Equipment Industry?
| 4 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
SPEC INSPECS Group | 0.3x | 5.5% | US$64.44m |
YGEN Yourgene Health | 0.6x | n/a | US$20.48m |
IHC Inspiration Healthcare Group | 0.4x | 13.6% | US$17.72m |
SUN Surgical Innovations Group | 0.4x | n/a | US$6.44m |
| 4 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: BELL is expensive based on its Price-To-Sales Ratio (12x) compared to the UK Medical Equipment industry average (3x).
Price to Sales Ratio vs Fair Ratio
What is BELL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 12x |
| Fair PS Ratio | 0.5x |
Price-To-Sales vs Fair Ratio: BELL is expensive based on its Price-To-Sales Ratio (12x) compared to the estimated Fair Price-To-Sales Ratio (0.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Arjo
SEK 9.3b
Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.
0HQ8
SEK 34.02
7D
0.4%
1Y
-6.6%
Centene
US$30.5b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
0HVB
US$61.32
7D
4.8%
1Y
-17.1%
Elevance Health
US$93.4b
Operates as a health benefits company in the United States.
0HG8
US$409.11
7D
2.1%
1Y
-14.2%